Financial Performance - Total revenues for Q1 2025 were $99.0 million, a 2% increase on a GAAP basis and a 4% increase on a non-GAAP constant currency basis compared to Q1 2024[7]. - Net loss for Q1 2025 was $(0.5) million, or $(0.01) per fully diluted share, compared to net income of $7.5 million, or $0.18 per fully diluted share in Q1 2024[8]. - Adjusted EBITDA for Q1 2025 increased by 1% to $17.5 million compared to $17.3 million in Q1 2024[5]. - Total revenues for the three months ended March 31, 2025, were $98,978, a 4% increase from $97,431 in the same period of 2024[25]. - Adjusted EBITDA for the three months ended March 31, 2025, was $17,548, compared to $17,312 in the same period of 2024[29]. - For the three months ended March 31, 2025, the company reported a net loss of $505 million compared to a net income of $7,533 million in the same period of 2024[31]. - The diluted loss per common share for the current quarter was $(0.01), a decrease from $0.18 in the prior year[31]. - Adjusted net income, non-GAAP, was $2,494 million, slightly down from $2,632 million in the previous year[31]. - The adjusted diluted income per common share, non-GAAP, remained stable at $0.06 for both periods[31]. Revenue Growth - Stent grafts revenue grew by 14%, On-X by 10%, and BioGlue by 7% year-over-year, with constant currency growth rates of 19%, 11%, and 9% respectively[4]. - Aortic stent grafts revenue increased by 14% to $36,602 from $32,103 year-over-year[27]. - The company raised its full-year 2025 revenue guidance to a range of $423 to $435 million, representing growth of 11% to 14% on a constant currency basis compared to 2024[9]. Expenses and Liabilities - General, administrative, and marketing expenses increased to $54.7 million in Q1 2025 from $30.7 million in Q1 2024[19]. - Cash and cash equivalents decreased to $37,693 as of March 31, 2025, from $53,463 at the end of 2024[23]. - Total current liabilities decreased to $51,940 from $66,823 year-over-year[23]. - Long-term debt remained stable at $314,611 compared to $314,152 year-over-year[21]. Cybersecurity Incident - The company experienced a significant cybersecurity incident, which contributed $4,746 million to the adjustments in the income statement[31]. Clinical and Regulatory Updates - 30-day data from Endospan's NEXUS TRIOMPHE IDE trial showed a 63% reduction in the major adverse event (MAE) rate compared to reference performance goals[5]. - The clinical module of the pre-market approval application (PMA) for the AMDS Hybrid Prosthesis has been submitted to the FDA[5]. - The company anticipates NEXUS to be on track for FDA approval in the second half of 2026[6]. Cash Flow and Other Financial Metrics - Free cash flows for the three months ended March 31, 2025, were $(20,591), compared to $(9,104) in the same period of 2024[29]. - Total assets increased to $791,163 as of March 31, 2025, from $789,101 at the end of 2024[21]. - Business development, integration, and severance income showed a notable improvement, with a reduction in losses from $(17,387) million to $(3,057) million[31]. - The company incurred a non-cash interest expense of $543 million, slightly down from $580 million in the previous year[31]. - The income tax benefit for the current quarter was $(1,790) million, compared to an expense of $5,248 million in the same quarter last year[31].

First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basis Net loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025 Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of ...

30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance GoalATLANTA, May 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle, Washington. The data presented analyzed ...

ATLANTA, April 21, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2025 financial results will be released on Monday, May 5, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion.To list ...

Artivion (AORT) shares ended the last trading session 7.9% higher at $23.95. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.5% loss over the past four weeks.Artivion stock surged amid a broader market rebound following the Trump administration’s announcement of a temporary halt on reciprocal tariffs for most countries. The move came in response to steep market declines and growing fears that tariff increases cou ...

Company Overview - Artivion, Inc. is a medical device company headquartered in suburban Atlanta, Georgia, focusing on solutions for cardiac and vascular surgeons dealing with aortic diseases [3] - The company offers four major product groups: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues [3] - Artivion markets and sells its products in over 100 countries worldwide [3] Upcoming Event - Artivion will participate virtually in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference [1] - The virtual fireside chat is scheduled to begin at 10:40 a.m. ET on March 18, 2025 [1] - A live webcast of the event will be available on Artivion's website, with an archived version accessible for 90 days [2]

Financial Performance - Total revenues for 2024 reached $388.5 million, an increase of 9.8% from $354.0 million in 2023[371]. - Product revenues increased to $290.2 million, up 11.1% from $261.2 million in 2023[371]. - Operating income for 2024 was $38.9 million, significantly higher than $5.7 million in 2023[371]. - Net loss decreased to $13.4 million in 2024 from $30.7 million in 2023, reflecting a reduction of 56.3%[371]. - Basic loss per share improved to $(0.32) from $(0.75) in 2023[371]. - Net loss for the year ended December 31, 2024, was $13,359 million, a decrease from a net loss of $30,690 million in 2023[373]. - Net cash flows provided by operating activities increased to $22,236 million in 2024 from $18,825 million in 2023[373]. - Total current assets increased to $290.1 million in 2024, up from $280.7 million in 2023[367]. - Total liabilities rose slightly to $512.9 million in 2024 from $510.6 million in 2023[369]. - Cash and cash equivalents decreased to $53.5 million in 2024 from $58.9 million in 2023[367]. Employee Relations and Workforce - The company had approximately 1,600 employees as of December 31, 2024, with a focus on attracting and retaining qualified personnel in a competitive market[146]. - The company has never experienced a work stoppage or interruption due to labor disputes, indicating good relations with employees worldwide[146]. - The company has programs in place to enhance compensation and benefits to attract and retain talent in the medical device and tissue processing industries[148]. - The company emphasizes a strong and collaborative culture, with core values focused on collaboration, results-driven performance, and customer focus[149]. Internal Controls and Compliance - The company maintains effective internal control over financial reporting as of December 31, 2024, based on the COSO criteria[359]. - The company’s independent auditor, Ernst & Young, LLP, issued an unqualified opinion on the effectiveness of internal controls over financial reporting as of December 31, 2024[347]. Risks and Sensitivities - The company’s operations are subject to risks from interest rate fluctuations and foreign currency exchange rate changes, which could significantly impact financial results[332][334]. - A hypothetical increase of one percentage point in interest rates on the company's variable rate debt portfolio would decrease pre-tax operating results by an estimated $2.0 million over a twelve-month period[333]. - A hypothetical 10% change in foreign currency exchange rates would decrease pre-tax operating results by an estimated $8.0 million over a twelve-month period[335]. Capital Expenditures and Investments - Capital expenditures for 2024 were $11,188 million, up from $9,752 million in 2023[373]. - The company completed the acquisition of Ascyrus Medical LLC to enhance the company's product offerings in the treatment of acute Type A aortic dissections[440]. - The total potential purchase consideration for the Ascyrus acquisition is up to $200.0 million, including cash payments and stock issuance upon achieving specific milestones[441]. Revenue and Market Performance - North America generated $197.9 million in revenue for 2024, up from $187.6 million in 2023, representing a growth of 7.2%[506]. - EMEA revenue increased to $131.5 million in 2024 from $114.8 million in 2023, reflecting a growth of 14.6%[506]. Stock and Equity - The company authorized a total of 10,045,000 shares under its stock plans as of December 31, 2024, with 2,742,000 shares available for grant[507]. - In 2024, the company authorized stock awards totaling 781,000 shares with an aggregate grant date market value of $16.2 million[508]. - The company did not authorize any grants of stock options during 2024, while 110,000 shares were granted in 2023[515]. Tax and Deferred Assets - Total deferred tax assets were $41.87 million as of December 31, 2024, down from $43.14 million in 2023, with a net deferred tax liability of $19.12 million[470]. - The company maintained a valuation allowance against deferred tax assets of $32.61 million as of December 31, 2024, compared to $32.86 million in 2023[470]. - As of December 31, 2024, the uncertain tax liability was $5.1 million, with $4.0 million expected to affect the tax rate if recognized[475]. Debt and Financing - The total principal debt as of December 31, 2024, was $320.2 million, with total debt amounting to $314.3 million after accounting for unamortized debt issuance costs[480]. - The company entered into a credit agreement for $350.0 million, including a $190.0 million secured term loan facility and a $60.0 million revolving credit facility[483]. - The stated interest rate for the Term Loan Facility was 11.09% as of December 31, 2024, with an effective interest rate of 11.86%[489]. - The company is in compliance with its debt covenants, which require a total net leverage ratio not greater than 6.25x for certain periods[487].

Core Viewpoint - Artivion (AORT) has experienced a significant downtrend, with an 18.6% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Stock Performance and Technical Indicators - AORT's stock has been under heavy selling pressure, indicated by an RSI reading of 17.29, which suggests that the selling may be exhausting itself and a trend reversal could be imminent [5]. - The Relative Strength Index (RSI) is a momentum oscillator that helps identify whether a stock is oversold, typically when the RSI falls below 30 [2][3]. Group 2: Earnings Estimates and Analyst Consensus - There is a strong consensus among sell-side analysts regarding AORT's ability to exceed previous earnings estimates, with a 36% increase in the consensus EPS estimate over the last 30 days [6]. - AORT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a near-term turnaround [7].

4Q and Full Year 2024 Earnings Presentation February 24, 2025 1 © 2025 Artivion, Inc. FORWARD-LOOKING STATEMENTS Statements made in this presentation that look forward in time or that express management's beliefs, expectations, or forecasts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our beliefs and expectations about ou ...

Financial Data and Key Metrics Changes - Total revenues for Q4 2024 were $97.3 million, up 3% compared to Q4 2023 [34] - Adjusted EBITDA increased approximately 15% from $15.3 million to $17.6 million in Q4 2024 [34] - For the full year, total revenues were $388.5 million, up 9.4% in constant currency and 10% excluding PerClot [35] - Adjusted EBITDA grew 32% for the full year, resulting in adjusted EBITDA margins of 18%, a 310 basis point improvement from 2023 [35][36] Business Line Data and Key Metrics Changes - On-X revenue increased 10% year-over-year on a constant currency basis [13] - Stent graft revenues grew 8% on a constant currency basis in Q4 compared to the same period last year [15] - BioGlue grew 7% on a constant currency basis compared to the same period last year [16] - Tissue processing declined 8% year-over-year on a constant currency basis in Q4 [18] Market Data and Key Metrics Changes - Latin America and Asia-Pacific delivered constant-currency revenue growth of 26% and 11% for the full year, respectively [19] - The company anticipates strong revenue growth for both regions over the coming years [19] Company Strategy and Development Direction - The company aims for sustained double-digit revenue growth and EBITDA growth at least twice the rate of revenue growth [7][31] - The Humanitarian Device Exemption (HDE) for AMDS represents a significant milestone, allowing for commercial distribution prior to PMA approval [21] - The company is focused on expanding its product pipeline and leveraging regulatory approvals to drive growth [20][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in recovering lost revenue from the cyber incident throughout 2025, citing strong underlying demand [77][81] - The company expects constant currency growth of between 10% and 14% for the full year 2025, with reported revenue ranging from $420 million to $435 million [51] - Management noted that the cyber incident would not have a meaningful impact on the business for the full year 2025 [38] Other Important Information - The cyber incident had an estimated negative impact of approximately $4.5 million on Q4 revenue and $2 million on adjusted EBITDA [9][37] - The company expects to incur additional cyber-related expenses in 2025 [45] - Free cash flow was $8.7 million in Q4 2024, with approximately $53.5 million in cash and $314.3 million in debt as of December 31 [48][49] Q&A Session Summary Question: Early AMDS commercial progress - Management reported that the U.S. commercial team is actively pursuing AMDS accounts, with 55 feet on the street [72] Question: Confidence in recovering lost revenue - Management expressed confidence that demand exceeds supply, and they expect to catch up on lost revenue due to normal donation levels [76][77] Question: PMA timeline delay for AMDS - The delay is due to new testing requirements from the FDA, which will add two quarters to the timeline [86] Question: Number of implanting sites for AMDS - There are about 1,000 centers that perform DeBakey type 1 dissections, with a focus on the top 600 centers for initial penetration [92] Question: Operational impact of the cyber incident - The incident required manual processing of tasks that would normally be automated, extending lead times [95] Question: Q1 adjusted EBITDA expectations - Q1 is expected to be the lowest adjusted EBITDA of the year, with revenue timing differences impacting results [98]